OptimizeRx Corporation
OPRXHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeOptimizeRx Corporation operates as a digital healthcare technology company. The company carries a $172.3M market cap, placing it firmly in the micro-cap category. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail.
Market Cap
$172.3M
Beta
1.26
P/E (TTM)
38.13
P/E (Fwd)
8.76
EPS (TTM)
$0.24
EPS (Fwd)
$1.04
ROE
3.7%
ROA
4.2%
Cash
$24.1M
Total Debt
$19.5M
Free CF
$15.8M
52W Change
-56.2%
Annual Financials
Cash vs Debt
Where OPRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, OPRX finished 31.03% above its 150-day moving average ($6.67) and 16.84% above its 200-day moving average ($7.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OPRX overbought or oversold?
At the October 20, 2026 close, OPRX's RSI(14) was 57.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $24.1M in cash comfortably exceeding the $19.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $15.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 3.7% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $62.5M (2022) to $109.4M (2025), reflecting a 75% increase over the period.
Investors considering OptimizeRx Corporation should weigh the typical risks associated with OPRX's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for OptimizeRx Corporation and its sector.